Recce Pharmaceuticals advances R327 Gel towards Phase 3 after promising Phase II trial
Recce Pharmaceuticals Limited has announced significant success in its Phase II trial of RECCE 327 topical gel (R327G), a synthetic anti-infective designed to treat acute ... Read More
Wockhardt’s Zaynich achieves record-breaking 96.8% clinical cure rate in cUTI Phase III trial
Wockhardt Limited has announced a major breakthrough in the treatment of complicated urinary tract infections (cUTI) with its novel antibiotic Zaynich (Zidebactam/Cefepime, WCK 5222). In ... Read More
Wockhardt secures approval for Miqnaf: A breakthrough in pneumonia treatment
In a landmark decision addressing the global challenge of antibiotic resistance, the Indian drug regulator, Central Drugs Standard Control Organization (CDSCO), has granted approval to ... Read More
Asep Medical adopts innovative AI approach to address antibiotic resistance
In a significant announcement at the US Biophysical Society in Philadelphia, Asep Medical Holdings Inc. (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) has shared a breakthrough ... Read More